Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA's perspective on rapid review for AIDS drugs

FDA's perspective on rapid review for AIDS drugs

WASHINGTON - FDA officials, including Commissioner David Kessler and David Feigal, director of the antiviral drug products division, reaffirmed the agency's commitment to rapid approval of AIDS drugs and provided some clues about the future course of accelerated review at a day-and-a-half-long meeting of the Antiviral Drugs Advisory Committee last week.

Outlining the FDA's requirements for AIDS trials, Feigal said,

Read the full 675 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE